Stroma-normalized vessel density predicts benefit from adjuvant chemotherapy in stage II/III colon cancer

Artur Mezheyeuski, Ina Hrynchyk, Eric Osterman, Mia Karlberg, Peter Ragnhammar, David Edler, Anna Portyanko, Fredrik Ponten, Tobias Sjöblom, Bengt Glimelius, Arne Östman

Determination of the ‘VDₙ’ (stroma-normalized vessel density) metric.

VDₙ is scored separately in:
- tumor center
- invasive margin
- peritumoral stroma

Computing VDₙ metric:
(vessel number per stroma area)

Discovery cohort
Nordic adjuvant randomized clinical trial investigating benefits of 5-FU-based chemotherapy in stage II/III CRC, n=285

Validation cohort
population-based CRC-collection of stage II/III colon cancers (U-CAN), n=203

Conclusion: Stroma-normalized vessel density in the invasive margin is a marker for patients benefiting from adjuvant 5-FU-based chemotherapy in stage II/III colon cancer